文件名称：Industry Update
文件大小：41KB
文件格式：PDF
更新时间：2024-07-19 15:09:45
学术 论文
Industry Update Industry Update Losing faith? There are increasing signs that large pharmaceutical and first-tier bio- pharmaceutical companies are with- drawing from direct research activity in gene therapy. The most notable casualty of this loss of faith has been Aventis’ GenCell Network, which appears to have ceased significant new investment in anything other than clinical programmes, following the creation of Aventis through the merger of Rhone Poulenc Rorer and Hoechst. Gene therapy-re